Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | UBX-303061 |
Synonyms | |
Therapy Description |
Limited information is currently available on UBX-303061, a putative BTK degrader (Dec 2024). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
UBX-303061 | UBX303061|UBX 303061 | BTK inhibitor 38 | Limited information is currently available on UBX-303061, a putative BTK degrader (Dec 2024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06590961 | Phase I | UBX-303061 | UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies | Recruiting | USA | POL | 1 |